X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11264) 11264
Book Chapter (106) 106
Conference Proceeding (30) 30
Dissertation (28) 28
Magazine Article (7) 7
Book / eBook (2) 2
Publication (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
acquired-resistance (6647) 6647
humans (4047) 4047
oncology (3442) 3442
systemic acquired-resistance (3086) 3086
plant sciences (2874) 2874
mutation (2258) 2258
animals (1759) 1759
cancer (1667) 1667
salicylic-acid (1651) 1651
biochemistry & molecular biology (1614) 1614
disease resistance (1581) 1581
female (1422) 1422
plants (1188) 1188
cell biology (1168) 1168
gefitinib (1153) 1153
lung neoplasms - drug therapy (1090) 1090
cell line, tumor (1066) 1066
signal transduction (1055) 1055
lung cancer (1051) 1051
research (1045) 1045
salicylic acid (1039) 1039
male (1029) 1029
genetic aspects (1019) 1019
proteins (983) 983
chemotherapy (980) 980
expression (972) 972
gene expression (971) 971
analysis (912) 912
systemic acquired resistance (905) 905
lung neoplasms - genetics (897) 897
tumors (893) 893
cell lung-cancer (877) 877
carcinoma, non-small-cell lung - drug therapy (875) 875
drug resistance (860) 860
antineoplastic agents - pharmacology (836) 836
antineoplastic agents - therapeutic use (813) 813
arabidopsis (811) 811
egfr (810) 810
pathogens (805) 805
open-label (794) 794
kinases (789) 789
mice (786) 786
drug resistance, neoplasm (784) 784
acquired resistance (778) 778
genes (778) 778
protein kinase inhibitors - pharmacology (776) 776
protein kinase inhibitors - therapeutic use (774) 774
tyrosine kinase inhibitors (768) 768
life sciences (763) 763
gene-expression (753) 753
health aspects (744) 744
growth-factor receptor (738) 738
arabidopsis-thaliana (733) 733
middle aged (725) 725
mutations (715) 715
erlotinib (711) 711
arabidopsis - genetics (707) 707
carcinoma, non-small-cell lung - genetics (689) 689
epidermal growth factor (674) 674
lung neoplasms - pathology (656) 656
induction (651) 651
care and treatment (647) 647
drug resistance, neoplasm - genetics (645) 645
receptor, epidermal growth factor - genetics (644) 644
aged (643) 643
plant diseases - microbiology (639) 639
receptor, epidermal growth factor - antagonists & inhibitors (633) 633
apoptosis (624) 624
pharmacology & pharmacy (622) 622
gene expression regulation, plant (616) 616
physiological aspects (610) 610
therapy (606) 606
biotechnology & applied microbiology (583) 583
lung cancer, non-small cell (580) 580
activation (572) 572
tyrosine (556) 556
metastasis (550) 550
fungi (547) 547
leaves (547) 547
cancer therapies (542) 542
melanoma (537) 537
salicylic acid - metabolism (535) 535
defense responses (526) 526
adult (524) 524
research article (523) 523
multidisciplinary sciences (521) 521
gene (518) 518
tobacco (512) 512
arabidopsis thaliana (507) 507
non-small cell lung cancer (503) 503
carcinoma, non-small-cell lung - pathology (500) 500
resistance (497) 497
signal transduction - drug effects (491) 491
molecular sequence data (490) 490
1st-line treatment (486) 486
arabidopsis proteins - genetics (486) 486
lung-cancer (483) 483
jasmonic acid (467) 467
tyrosine kinase inhibitor (464) 464
patients (463) 463
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11203) 11203
Japanese (138) 138
French (55) 55
Chinese (41) 41
Portuguese (33) 33
German (20) 20
Spanish (14) 14
Korean (7) 7
Polish (7) 7
Russian (7) 7
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer discovery, ISSN 2159-8290, 2016, Volume 6, Issue 10, pp. 1118 - 1133
Journal Article
Journal Article
Cancer Discovery, ISSN 2159-8274, 2013, Volume 3, Issue 6, pp. 658 - 673
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2018, Volume 29, Issue suppl_1, pp. i20 - i27
Abstract Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for... 
Osimertinib | EGFR TKI | Acquired resistance | NSCLC | PHASE-III | ACQUIRED-RESISTANCE | T790M MUTATION | OPEN-LABEL | INHIBITOR AZD9291 | SINGLE-ARM | acquired resistance | CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | ONCOLOGY | osimertinib | BRAIN METASTASES | TUMOR DNA
Journal Article
Science translational medicine, ISSN 1946-6242, 2015, Volume 7, Issue 302, pp. 302ra133 - 302ra133
The identification of early-stage breast cancer patients at high risk of relapse would allow tailoring of adjuvant therapy approaches. We assessed whether... 
MEDICINE, RESEARCH & EXPERIMENTAL | EVOLUTION | THERAPY | PLASMA | ACQUIRED-RESISTANCE | FGFR3 | CELL BIOLOGY | Neoplasm, Residual | Recurrence | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Humans | Breast Neoplasms - blood | Female | High-Throughput Nucleotide Sequencing | DNA, Neoplasm - genetics | Mutation | Precision Medicine
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2015, Volume 112, Issue 30, pp. 9166 - 9173
Journal Article
Cancer discovery, ISSN 2159-8290, 2018, Volume 8, Issue 9, pp. 1130 - 1141
BRAF hyperactivates ERK and signals as a RAF inhibitor-sensitive monomer. Although RAF inhibitors can produce impressive clinical responses in patients with... 
BRAF V600E | secondary mutation | dabrafenib | acquired resistance
Journal Article
Oncogenesis (New York, NY), ISSN 2157-9024, 2013, Volume 2, Issue 3, pp. e39 - e39
Despite initial and often dramatic responses of epidermal growth factor receptor (EGFR)-addicted lung tumors to the EGFR-specific tyrosine kinase inhibitors... 
gefitinib | NSCLC | FGF2 | acquired resistance | EGFR | FGFR1 | FACTOR-RECEPTOR | TARGETED THERAPY | ACQUIRED-RESISTANCE | T790M MUTATION | MESENCHYMAL TRANSITION | CHEMOTHERAPY | TYROSINE KINASE INHIBITORS | LUNG-CANCER | MET AMPLIFICATION | ONCOLOGY | CARCINOMA | Original
Journal Article
Cancer discovery, ISSN 2159-8290, 2018, Volume 8, Issue 6, pp. 714 - 729
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2015, Volume 13, Issue 5, pp. 515 - 524
These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very... 
TYROSINE KINASE INHIBITORS | CLINICOPATHOLOGICAL CHARACTERISTICS | MOLECULAR-PATHOLOGY | ESMO CONSENSUS CONFERENCE | GROWTH-FACTOR-RECEPTOR | ALK GENE REARRANGEMENT | ONCOLOGY | ACQUIRED-RESISTANCE | EGFR MUTATION | TUMOR SPECIMENS | PERSONALIZED CANCER
Journal Article